2024
Procedure Volume and Outcomes With WATCHMAN Left Atrial Appendage Occlusion
Friedman D, Du C, Zimmerman S, Tan Z, Lin Z, Vemulapalli S, Kosinski A, Piccini J, Pereira L, Minges K, Faridi K, Masoudi F, Curtis J, Freeman J. Procedure Volume and Outcomes With WATCHMAN Left Atrial Appendage Occlusion. Circulation Cardiovascular Interventions 2024, 17: e013466. PMID: 38889251, PMCID: PMC11189610, DOI: 10.1161/circinterventions.123.013466.Peer-Reviewed Original ResearchConceptsVolume-outcome relationshipLikelihood of procedural successLeft atrial appendage occlusionProcedural successProcedure volumeAppendage occlusionNational Cardiovascular Data Registry LAAO RegistryVolume quartilesLeft atrial appendage occlusion devicesThree-level hierarchical generalized linear modelsMinimum volume thresholdsWatchman FLX deviceProcedural success rateHierarchical generalized linear modelsAssociated with outcomePhysician volumeWATCHMAN procedureFLX deviceOcclusion deviceVolume thresholdCardiovascular proceduresPhysiciansHospitalNational analysisSuccess rate
2022
Days at home after transcatheter or surgical aortic valve replacement in high-risk patients
Chung M, Butala N, Faridi K, Almarzooq Z, Liu D, Xu J, Song Y, Baron S, Shen C, Kazi D, Yeh R. Days at home after transcatheter or surgical aortic valve replacement in high-risk patients. American Heart Journal 2022, 255: 125-136. PMID: 36309128, DOI: 10.1016/j.ahj.2022.10.080.Peer-Reviewed Original ResearchConceptsSurgical aortic valve replacementTranscatheter aortic valve replacementHigh-risk patientsAortic valve replacementHigh-risk trialsValve replacementIndex hospitalizationRisk trialsLong-term acute care hospitalSelf-expanding bioprosthesisAcute care hospitalsSkilled nursing facilitiesPatient-centered perspectiveFirst yearIndex LOSTAVR patientsCare hospitalEmergency departmentObservation staysPostprocedural courseLandmark analysisMedicare feeNursing facilitiesService claimsPatients
2021
Applicability of Transcatheter Aortic Valve Replacement Trials to Real-World Clinical Practice Findings From EXTEND-CoreValve
Butala NM, Secemsky E, Kazi DS, Song Y, Strom JB, Faridi KF, Brennan JM, Elmariah S, Shen C, Yeh RW. Applicability of Transcatheter Aortic Valve Replacement Trials to Real-World Clinical Practice Findings From EXTEND-CoreValve. JACC Cardiovascular Interventions 2021, 14: 2112-2123. PMID: 34620389, PMCID: PMC8855223, DOI: 10.1016/j.jcin.2021.08.006.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacement (TAVR) trialsReal-world patientsReal-world populationTrial patientsPivotal trialsClinical practiceTreatment effectsReplacement trialsAbsolute reductionClinical practice findingsU.S. clinical practiceCharacteristics of patientsCongestive heart failureTrial treatment effectPatient characteristicsTrial cohortHeart failureMedicare cohortAbsolute benefitConventional therapyClinical trialsInverse probability weightingMedicare patientsTAVRMedicare beneficiariesNew Heart Failure After Myocardial Infarction (From the National Cardiovascular Data Registries [NCDR] Linked With All-Payer Claims)
Faridi KF, Bhalla N, Atreja N, Venditto J, Khan ND, Wilson T, Fonseca E, Shen C, Yeh RW, Secemsky EA. New Heart Failure After Myocardial Infarction (From the National Cardiovascular Data Registries [NCDR] Linked With All-Payer Claims). The American Journal Of Cardiology 2021, 151: 70-77. PMID: 34053629, DOI: 10.1016/j.amjcard.2021.04.019.Peer-Reviewed Original ResearchConceptsIncident heart failureChronic kidney diseaseAcute myocardial infarctionAdvanced chronic kidney diseaseConcurrent heart failureRecurrent myocardial infarctionHeart failureMyocardial infarctionRisk scoreNational Cardiovascular Data Registry CathPCIChest Pain-MI RegistryHistory of HFNew-onset heart failureTime of MINew heart failureSimplified risk scoreOnset heart failureIndex myocardial infarctionFuture heart failureAfrican American raceSpecific risk factorsCumulative incidenceIndependent predictorsKidney diseaseRisk factors
2020
Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment–Elevation Myocardial Infarction in the United States
Faridi KF, Garratt KN, Kennedy KF, Maddox TM, Secemsky EA, Butala NM, Yeh RW. Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment–Elevation Myocardial Infarction in the United States. Circulation Cardiovascular Quality And Outcomes 2020, 13: e006275. PMID: 32156164, DOI: 10.1161/circoutcomes.119.006275.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiologistsCardiology Service, HospitalClopidogrelDrug UtilizationFemaleHemorrhageHumansMaleMiddle AgedPatient DischargePercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPractice Patterns, Physicians'Prasugrel HydrochloridePurinergic P2Y Receptor AntagonistsReceptors, Purinergic P2Y12RegistriesRetrospective StudiesRisk AssessmentRisk FactorsST Elevation Myocardial InfarctionTicagrelorTime FactorsTreatment OutcomeUnited StatesConceptsST-segment elevation myocardial infarctionP2Y12 inhibitor usePotent P2Y12 inhibitorsP2Y12 inhibitorsSTEMI patientsMyocardial infarctionInhibitor useClopidogrel usePrior percutaneous coronary interventionNew P2Y12 inhibitorsSubstantial hospital variationUse of ticagrelorElevation myocardial infarctionPercutaneous coronary interventionRisk of deathStrongest clinical predictorsNational utilization ratesBackground TicagrelorHospital quartilesCoronary interventionPatient characteristicsClinical predictorsTicagrelor useHospital variationRetrospective study
2019
Comparison of Clinical Trials and Administrative Claims to Identify Stroke Among Patients Undergoing Aortic Valve Replacement
Strom JB, Zhao Y, Faridi KF, Tamez H, Butala NM, Valsdottir LR, Curtis J, Brennan JM, Shen C, Boulware M, Popma JJ, Yeh RW. Comparison of Clinical Trials and Administrative Claims to Identify Stroke Among Patients Undergoing Aortic Valve Replacement. Circulation Cardiovascular Interventions 2019, 12: e008231. PMID: 31694411, PMCID: PMC7212938, DOI: 10.1161/circinterventions.119.008231.Peer-Reviewed Original ResearchMeSH KeywordsAdministrative Claims, HealthcareAgedAged, 80 and overAortic ValveAortic Valve StenosisBrain IschemiaClinical Trials as TopicDatabases, FactualFemaleHeart Valve Prosthesis ImplantationHumansIschemic Attack, TransientMaleMedicareRisk AssessmentRisk FactorsStrokeTime FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeUnited StatesConceptsNegative predictive valueAortic valve replacementCerebrovascular eventsInternational ClassificationPositive predictive valuePredictive valueValve replacementNinth RevisionClinical trialsTenth RevisionBilling codesKaplan-Meier estimatesMedicare inpatient claimsSURTAVI trialClinical event adjudicationDevastating complicationIschemic strokeNeurological eventsCerebrovascular diseaseBilling claimsInpatient claimsEvent adjudicationAdministrative claimsHigh riskTrial participants
2018
The Value of Claims-Based Nontraditional Risk Factors in Predicting Long-term Mortality After MitraClip Procedure
Kundi H, Popma JJ, Valsdottir LR, Shen C, Faridi KF, Pinto DS, Yeh RW. The Value of Claims-Based Nontraditional Risk Factors in Predicting Long-term Mortality After MitraClip Procedure. Canadian Journal Of Cardiology 2018, 34: 1648-1654. PMID: 30527154, PMCID: PMC6424362, DOI: 10.1016/j.cjca.2018.10.002.Peer-Reviewed Original ResearchConceptsNontraditional risk factorsLong-term mortalityNoncardiac risk factorsMitral valve repairRisk factorsValve repairMitraClip procedureClaims dataLong-term mortality riskPercutaneous mitral valve repairTranscatheter mitral valve repairPredicting Long-Term MortalityCardiac risk factorsPresentation characteristicsCox regression modelAdministrative claims dataRisk prediction modelMedian followMitraClip implantationModel discriminationMortality riskClaims codesMedicare feePatientsService beneficiaries
2017
Serum vitamin D and change in lipid levels over 5 y: The Atherosclerosis Risk in Communities study
Faridi KF, Zhao D, Martin SS, Lupton JR, Jones SR, Guallar E, Ballantyne CM, Lutsey PL, Michos ED. Serum vitamin D and change in lipid levels over 5 y: The Atherosclerosis Risk in Communities study. Nutrition 2017, 38: 85-93. PMID: 28526388, PMCID: PMC5443111, DOI: 10.1016/j.nut.2017.01.008.Peer-Reviewed Original ResearchConceptsIncident dyslipidemiaLipid changesLongitudinal community-based studyAdjusted average differencesDemographic-adjusted modelsLipid-lowering therapySerum vitamin DCommunity-based studyBaseline dyslipidemiaLipid trendsIncident useCardiovascular riskClinical characteristicsSD ageVitamin DARIC studyAtherosclerosis RiskCardiovascular diseaseLipid levelsDyslipidemiaCommunity studyRatio of TCHDLMixed effects modelsBaseline
2015
Remnant Lipoprotein Cholesterol and Mortality After Acute Myocardial Infarction: Further Evidence for a Hypercholesterolemia Paradox From the TRIUMPH Registry
Martin SS, Faridi KF, Joshi PH, Blaha MJ, Kulkarni KR, Khokhar AA, Maddox TM, Havranek EP, Toth PP, Tang F, Spertus JA, Jones SR. Remnant Lipoprotein Cholesterol and Mortality After Acute Myocardial Infarction: Further Evidence for a Hypercholesterolemia Paradox From the TRIUMPH Registry. Clinical Cardiology 2015, 38: 660-667. PMID: 26459191, PMCID: PMC4715617, DOI: 10.1002/clc.22470.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkersChi-Square DistributionCholesterolFemaleHumansHypercholesterolemiaKaplan-Meier EstimateLinear ModelsLipoproteinsMaleMiddle AgedMyocardial InfarctionProportional Hazards ModelsProspective StudiesProtective FactorsRegistriesRisk AssessmentRisk FactorsTime FactorsTriglyceridesUnited StatesUp-RegulationConceptsAcute myocardial infarctionHigh RLP-C levelsRLP-C levelsRemnant lipoprotein cholesterolLipoprotein cholesterolHazard ratioMyocardial infarctionAcute Coronary Events (GRACE) scoreIntermediate-density lipoprotein cholesterolLow-density lipoprotein cholesterolLipoprotein cholesterol subfractionsMortality 2 yearsUnknown protective factorsLead-time biasRegression hazard ratiosTriglyceride-rich lipoproteinsPrior observational studiesTRIUMPH registryCholesterol subfractionsLowest tertileAMI outcomesAMI survivorsHypercholesterolemic patientsMiddle tertileGlobal RegistryRelationship of the triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio to the remainder of the lipid profile: The Very Large Database of Lipids-4 (VLDL-4) study
Quispe R, Manalac RJ, Faridi KF, Blaha MJ, Toth PP, Kulkarni KR, Nasir K, Virani SS, Banach M, Blumenthal RS, Martin SS, Jones SR. Relationship of the triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio to the remainder of the lipid profile: The Very Large Database of Lipids-4 (VLDL-4) study. Atherosclerosis 2015, 242: 243-250. PMID: 26232164, DOI: 10.1016/j.atherosclerosis.2015.06.057.Peer-Reviewed Original ResearchConceptsHigh-density lipoprotein cholesterol ratioLipoprotein cholesterol ratioLipid profileLDL densityCholesterol ratioAtherogenic lipid phenotypeLevels of RLPMedian TgMetabolic syndromeLipid parametersCohort representativeInsulin resistanceMean ageStudy populationElevated TGGeneral U.S.Higher RLPUS individualsLipid phenotypesDemographic informationHighest relative increaseTriglyceridesRLPAgeRelative increase